8,754 Shares in Vaxcyte, Inc. $PCVX Purchased by AXQ Capital LP

AXQ Capital LP acquired a new position in shares of Vaxcyte, Inc. (NASDAQ:PCVX) during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund acquired 8,754 shares of the company’s stock, valued at approximately $285,000.

Several other institutional investors and hedge funds also recently made changes to their positions in PCVX. US Bancorp DE raised its holdings in Vaxcyte by 7.2% in the first quarter. US Bancorp DE now owns 5,344 shares of the company’s stock valued at $202,000 after acquiring an additional 357 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Vaxcyte by 1.5% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 29,635 shares of the company’s stock valued at $1,119,000 after buying an additional 436 shares during the last quarter. KLP Kapitalforvaltning AS raised its stake in Vaxcyte by 2.2% during the first quarter. KLP Kapitalforvaltning AS now owns 23,000 shares of the company’s stock valued at $868,000 after buying an additional 500 shares in the last quarter. PNC Financial Services Group Inc. grew its position in shares of Vaxcyte by 5.8% in the 1st quarter. PNC Financial Services Group Inc. now owns 9,600 shares of the company’s stock worth $362,000 after acquiring an additional 524 shares in the last quarter. Finally, Hsbc Holdings PLC increased its holdings in shares of Vaxcyte by 3.1% in the 1st quarter. Hsbc Holdings PLC now owns 18,461 shares of the company’s stock valued at $675,000 after acquiring an additional 552 shares during the last quarter. 96.78% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have commented on PCVX. Leerink Partners set a $77.00 price objective on shares of Vaxcyte and gave the stock an “outperform” rating in a report on Wednesday, November 19th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vaxcyte in a research report on Tuesday, October 14th. The Goldman Sachs Group started coverage on shares of Vaxcyte in a research note on Friday, September 12th. They set a “neutral” rating and a $38.00 price objective on the stock. Cowen restated a “buy” rating on shares of Vaxcyte in a research note on Thursday, August 7th. Finally, BTIG Research reaffirmed a “buy” rating and set a $85.00 target price on shares of Vaxcyte in a report on Monday, November 10th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $97.83.

Vaxcyte Stock Performance

Shares of PCVX opened at $49.25 on Tuesday. The firm has a market capitalization of $6.45 billion, a price-to-earnings ratio of -10.18 and a beta of 1.06. Vaxcyte, Inc. has a one year low of $27.66 and a one year high of $94.76. The stock’s fifty day moving average is $41.44 and its 200-day moving average is $36.12.

Vaxcyte (NASDAQ:PCVX) last posted its quarterly earnings data on Tuesday, November 4th. The company reported ($1.56) earnings per share for the quarter, missing the consensus estimate of ($1.27) by ($0.29). During the same period last year, the business earned ($0.83) EPS. Analysts forecast that Vaxcyte, Inc. will post -4.21 EPS for the current fiscal year.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.